Human DNA Vaccine Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application (Oncology, Tuberculosis, HIV, Others), By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Human DNA Vaccine Market is projected for substantial growth, expanding from USD 371.02 Million in 2025 to USD 581.28 Million by 2031, demonstrating a CAGR of 7.77%. These advanced immunizing agents leverage genetically engineered plasmid DNA to induce antigen production within host cells, thereby stimulating comprehensive humoral and cellular immune responses. Key drivers for this market expansion include the exceptional thermal stability of DNA vaccines, which significantly reduces the reliance on cold-chain logistics, and the rapid pace of plasmid manufacturing, enabling swift deployment during infectious disease outbreaks. These distinct operational advantages set DNA technology apart from traditional vaccine modalities and are propelling its increasing application, particularly in oncology and against emerging infectious diseases. The escalating global burden of infectious diseases and zoonotic outbreaks serves as a primary catalyst, with DNA platforms offering rapid adaptability and scalability crucial for addressing novel threats and pathogens that elude conventional immunization. For instance, the World Health Organization's October 2024 'Global Tuberculosis Report' highlighted 8.2 million new TB diagnoses in 2023, the highest recorded, underscoring the urgent demand for next-generation DNA vaccines. Concurrently, technological advancements in DNA vaccine delivery systems, such as electroporation and needle-free jet injection devices, are overcoming historical barriers related to cellular uptake and immunogenicity. These innovations enhance plasmid entry into cell nuclei, amplifying the immune response without invasive administration, as evidenced by PharmaJet's October 2024 report on its needle-free systems being utilized in over 52 clinical studies across infectious disease and oncology programs. Such improvements are particularly vital for the expanding oncology segment, where precise immune stimulation is critical, especially with projections from the American Cancer Society of over 2 million new cancer cases in the United States in 2025, fueling the development of personalized DNA immunotherapies.
Market Driver
The escalating global burden of infectious diseases and zoonotic outbreaks serves as a primary catalyst for the Global Human DNA Vaccine Market. DNA platforms offer rapid adaptability and scalability, making them uniquely positioned to address emerging threats and prevalent pathogens that evade traditional immunization methods. This modality allows for the quick design of vaccine candidates against novel viral targets, a capability that is increasingly critical as respiratory and bacterial infections resurge worldwide. According to World Health Organization, October 2024, in the 'Global Tuberculosis Report 2024', approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest number recorded since global monitoring began. This rising incidence underscores the urgent demand for next-generation DNA vaccines capable of providing robust protection against complex pathogens where conventional approaches have historically fallen short. Simultaneously, technological advancements in DNA vaccine delivery systems are overcoming historical barriers related to cellular uptake and immunogenicity. Innovations in electroporation and needle-free jet injection devices are enhancing the efficiency of plasmid entry into cell nuclei, thereby amplifying the immune response without the discomfort of invasive administration. According to PharmaJet, October 2024, in a press release regarding the World Vaccine Congress, its needle-free injection systems are now being utilized in over 52 clinical studies across infectious disease and oncology development programs. These delivery improvements are particularly vital for the expanding oncology segment, where precise immune stimulation is required to target tumor-associated antigens. According to American Cancer Society, in 2025, over 2 million new cancer cases are projected to be diagnosed in the United States, driving the intensified development of personalized DNA immunotherapies utilizing these advanced delivery platforms.
Market Challenge
A primary challenge impeding the broader adoption of human DNA vaccines is the inherent difficulty in achieving sufficient immunogenicity in humans, often necessitating the use of invasive delivery systems like electroporation to ensure adequate cellular uptake. While plasmid DNA offers thermal stability, its poor cellular uptake via standard injection requires specialized devices to deliver electrical pulses, significantly increasing patient discomfort and logistical complexity. This operational cost and technical burden often negate the stability advantages, making these vaccines less viable for widespread mass immunization compared to more user-friendly competitors. Consequently, this delivery barrier restricts the market's expansion, confining the technology largely to niche therapeutic areas rather than high-volume infectious disease prevention. The International Federation of Pharmaceutical Manufacturers & Associations noted in late 2024 that a majority of 50 competing vaccine candidates for WHO priority pathogens utilized established delivery modalities that do not require additional hardware, highlighting the struggle for DNA vaccines tied to invasive electroporation equipment to capture significant market share against these more accessible alternatives.
Market Trends
The market is undergoing significant transformation through two key trends. Firstly, the transition to Minicircle and Linear DNA Vector Architectures is revolutionizing production by shifting from bacterial plasmid fermentation to cell-free, enzymatic methods. This innovation eliminates antibiotic resistance genes, drastically accelerates manufacturing timelines, and ensures higher purity and safety for human administration. The commercial viability of this technology is evident, with Touchlight reporting in July 2024 that its enzymatic dbDNA technology has been implemented in client products with three accepted Investigational New Drug (IND) or Clinical Trial Applications (CTAs), allowing developers to bypass regulatory and logistical bottlenecks of conventional plasmid manufacturing. Secondly, the emergence of Personalized Neoantigen Cancer Vaccines represents a paradigm shift toward precision oncology therapeutics. These vaccines are designed to target patient-specific tumor mutations, utilizing genomic sequencing to engineer plasmids that induce a potent, individualized T-cell response against unique cancer antigens. Geneos Therapeutics, in an April 2024 press release, substantiated this therapeutic potential by reporting a 30.6% Overall Response Rate (ORR) with its personalized DNA vaccine GNOS-PV02 in patients with advanced hepatocellular carcinoma, showcasing the platform's capacity to deliver effective immunotherapies in complex oncology settings where standard treatments frequently fall short.
Key Market Players
* BOEHRINGER INGELHEIM GmbH
* ELI-LILLY and Companay
* Gene One Life Science Inc,
* GEOVAX LABS, INC
* Inovio Pharmaceuticals Inc.
* Genexine, Inc.
* VIATRIS INC.
* Takara Holdings Inc.
* ZOETIS INC.
* Zydus Lifesciences Limited
Report Scope
In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Human DNA Vaccine Market, By Route of Administration
* Intramuscular
* Subcutaneous
* Intradermal
* Others
# Human DNA Vaccine Market, By Application
* Oncology
* Tuberculosis
* HIV
* Others
# Human DNA Vaccine Market, By End User
* Hospitals & Clinics
* Biotechnology & Pharmaceutical Companies
* Academic & Research Institutions
* Others
# Human DNA Vaccine Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.
Available Customizations:
Global Human DNA Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Human DNA Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Human DNA Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Human DNA Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Human DNA Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Human DNA Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. Europe Human DNA Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human DNA Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. France Human DNA Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. United Kingdom Human DNA Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. Italy Human DNA Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain Human DNA Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. Asia Pacific Human DNA Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Human DNA Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India Human DNA Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. Japan Human DNA Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Human DNA Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Human DNA Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. Middle East & Africa Human DNA Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Human DNA Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. UAE Human DNA Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. South Africa Human DNA Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. South America Human DNA Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Human DNA Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Colombia Human DNA Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. Argentina Human DNA Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Human DNA Vaccine Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. BOEHRINGER INGELHEIM GmbH
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. ELI-LILLY and Companay
15.3. Gene One Life Science Inc,
15.4. GEOVAX LABS, INC
15.5. Inovio Pharmaceuticals Inc.
15.6. Genexine, Inc.
15.7. VIATRIS INC.
15.8. Takara Holdings Inc.
15.9. ZOETIS INC.
15.10. Zydus Lifesciences Limited
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們